DNL.L Share News (DNL)

DNL.L Information

There is currently no data for DNL

UK Shareholder Meetings Calendar - Next 7 Days

Fri, 13th Nov 2020 16:06

Monday 16 November
Smiths Group PLC	AGM
JPMorgan Brazil Investment Trust PLC	GM re liquidation of company
European Opportunities Trust PLC	AGM
Tuesday 17 November
Dunelm Group PLC	AGM
BMO Real Estate Investments Ltd	AGM
Mulberry Group PLC	AGM
Scancell Holdings PLC	AGM
Physiomics PLC	AGM
Marwyn Value Investors Ltd	AGM
Craneware PLC	AGM
Shaftesbury PLC	GM re share issue resolutions
SIG PLC	GM re new remuneration policy
Wednesday 18 November
Beeks Financial Cloud Group PLC	AGM
Henderson Eurotrust PLC	AGM
Exillon Energy PLC	EGM re stock listing cancellation
Avingtrans PLC	AGM
Rainbow Rare Earths Ltd	AGM
Origin Enterprises PLC	AGM
Countrywide PLC	GM re proposed recapitalisation
Thursday 19 November
Close Brothers Group PLC	AGM
FW Thorpe PLC	AGM
William Hill PLC	GM re acquisition by Caesars Group
Jupiter UK Growth Investment Trust PLC	AGM
Finsbury Food Group PLC	AGM
Maestrano Group PLC	AGM
Randall & Quilter Investment Holdings Ltd	GM - re capital return
Infrastructure India PLC	AGM
Gresham House Energy Storage Fund PLC	GM re share issue, changes to investment policy
Friday 20 November
Salt Lake Potash Ltd	AGM
Diurnal Group PLC	AGM
Go-Ahead Group PLC	AGM
MC Mining Ltd	AGM
GSTechnologies Ltd	AGM
Gulf Investment Fund PLC	AGM

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News

2 Dec 2019 13:19

Diurnal submits application for 'Alkindi Sprinkle' to US FDA

(Sharecast News) - Specialty pharmaceutical company Diurnal Group has submitted a 'New Drug Application' (NDA) to the US Food and Drug Administration (FDA), for the regulatory approval of 'Alkindi Sprinkle', or hydrocortisone granules in capsules for opening, as a replacement therapy of adrenal insufficiency in infants, children and adolescents in the US, it announced on Monday.

21 Nov 2019 11:36

Diurnal Primary Focus Remains On Progressing Flagship Products

20 Nov 2019 11:36

Diurnal To Explore Further Tests As Testosterone Treatment Does Well

24 Sep 2019 11:21

Diurnal Loss Narrows On Research Expenses And Alkindi Launch

14 Jun 2019 14:26

Diurnal Shareholders Approve Placing, Open Offer Worth GBP6 Million (ALLISS)

(Alliance News) - Pharmaceutical firm Diurnal Group PLC's shareholders on Friday approved its GBP5.9 million fundraise completed earlier in the day.Diurnal, which focuses on patients or

28 May 2019 13:32

Diurnal Group launches placing and open offer to fund drug development

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced a conditional placing of new ordinary shares in the company and the launch of an open offer on Tuesday, in order to raise funds to progress the development and commercialisation of its products.

28 May 2019 10:49

Diurnal Raises GBP5 Million Via Placing; Plans GBP1 Million Open Offer (ALLISS)

LONDON (Alliance News) - Diurnal Group PLC said Tuesday it has raised around GBP5.4 million via a 20.6 million share placing priced at 26 pence per share and announced an open offer to raise up to

10 May 2019 09:36

Polar Capital Global Healthcare Lags Behind Benchmark In First Half

LONDON (Alliance News) - Polar Capital Global Healthcare Trust PLC said on Friday it lagged against its benchmark for the first half of its financial year, as the healthcare trust underperformed a

24 Apr 2019 15:50

Diurnal gets orphan drug designation for Alkindi in Australia

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Wednesday that its 'Alkindi' product - hydrocortisone granules in capsules for opening - had been granted orphan drug designation in Australia by the Therapeutic Goods Administration, for the indication 'replacement therapy of adrenal insufficiency (AI) in infants, children and adolescents from birth to 18 years old'.

24 Apr 2019 10:44

Diurnal Gets Orphan Drug Designation For Alkindi In Australia

LONDON (Alliance News) - Diurnal Group PLC on Wednesday said its adrenal insufficiency drug Alkindi has been granted a second patent and orphan drug designation in Australia.Shares in were

28 Mar 2019 08:35

Diurnal soars after securing Nordic distribution deal

(Sharecast News) - Diurnal's shares leapt on Thursday despite a widened interim loss as the company landed a marketing and distribution deal for its Alkindi treatment in Scandinavia.

21 Mar 2019 16:11

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 22 March Sanne GroupFull Year ResultsSmiths GroupHalf Year BootFull Year

20 Mar 2019 10:33

Diurnal Group upbeat following FDA meeting over 'Alkindi'

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Wednesday that, following a "positive" meeting with the US Food and Drug Administration (FDA), it intended to submit a new drug application (NDA) for 'Alkindi' (hydrocortisone granules in capsules for opening) in the fourth quarter of 2019 as previously planned, with final acceptance of the filing by the FDA expected in 2020.

25 Feb 2019 10:39

Diurnal expecting Israel launch of 'Alkindi' next year

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Monday that its marketing and distribution partner, Medison Pharma has successfully submitted a market authorisation application (MAA) for its 'Alkindi' (hydrocortisone granules in capsules for opening) product to the Ministry of Health in Israel.

10 Jan 2019 12:35

Diurnal Granted US Patent But Unsure Why Share Price Has Tripled

LONDON (Alliance News) - Diurnal Group PLC said on Thursday that, aside from the granting of a patent, it is unsure as to why its share price has tripled.Shares were 188% higher on Thursday

Latest Share Chat

DNL.L Share News (DNL)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Shareholder Meetings Calendar - Next 7 Days

Login to your account

Quickpicks are a member only feature

Login to your account